Table 3.

Features and approved synergistic drug combinations corresponding to top-10 coefficients.

Target 1	Target 2	Approved synergistic combination	Disease
Progesterone receptor	Estrogen receptor	Estrogens, conjugated; Medroxyprogesterone acetate	Symptoms of menopause  [18]
		Ethinyl Estradiol; Norethindrone	Contraception  [1]
Angiotensin-converting enzyme (ACE)	Type-1 angiotensin II receptor (AR)	Lisinopril; Losartan	Kidney Diseases  [17]
DDP-4	PPAR-γ	Rosiglitazone; Saxagliptin	Diabetes Mellitus, Type 2  [23,32,33]
		Alogliptin; Pioglitazone	Type 2 Diabetes Mellitus  [14,48]
Glucocorticoid receptor	Beta-2 adrenergic receptor	Fluticasone Propionate; Formoterol	Asthma, Bronchial  [5,13,42]
		Budesonide; Formoterol	Chronic Obstructive Pulmonary Disease; Asthma; Bronchiectasis  [46,59]
5′-AMPK	DDP-4	Alogliptin benzoate; Metformin Hydrochloride	Type 2 Diabetes Mellitus  [2]
		Metformin; Sitagliptin	Type 2 diabetes who do not use daily insulin injections; Diabetes Mellitus, Type 2  [57]
DNA	Ribonucleoside-diphosphate reductase subunit M2	Fluorouracil; SC144	Colorectal cancer  [40]
Renin	AR	Aliskiren; Irbesartan	Hypertension  [40]
Progesterone receptor	GnRH	Leuprorelin acetate; Acetynone acetonidone	For initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms  [40]
Follicle-stimulating hormone receptor	GnRH-R	Buserelin; Pregnyl	Ovarian Hyperstimulation  [25]
Angiotensin-converting enzyme	Voltage-dependent calcium channel gamma-1 subunit	None approved in DCDB